We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CXT:NYSECrane NXT, Co. Analysis

Data as of 2026-03-28 - not real-time

$41.15

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Crane NXT, Co. (CXT) is trading at $41.15, well below its 20‑day SMA of 43.92, 50‑day SMA of 48.68 and 200‑day SMA of 55.94, indicating a short‑term bearish bias. However, the MACD line has crossed above its signal line (‑2.174 vs ‑2.239) and the histogram turned positive, suggesting a potential bullish reversal, while the RSI of 31.4 hints at near‑oversold conditions. The stock sits just above its identified support at 40.01 and below a resistance near 49.59, giving it room to test higher levels if momentum holds. Volume remains stable, and the recent options activity noted in the news underscores market attention to possible upside moves.
Fundamentally, CXT delivers strong top‑line growth of 19.5% YoY, solid gross margin (~42%) and operating margin (~18%). The DCF‑derived fair value of $61.56 translates to an implied upside of roughly 77%, while its forward P/E of 8.7 is well below the industry average of 28.1, marking the stock as undervalued. Dividend sustainability looks robust with a modest payout ratio of 27% and a yield of 1.75%. Nevertheless, the company’s beta above 1.2, 30‑day volatility near 30%, and historical max drawdown of ‑41% signal heightened risk that investors must weigh.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near technical support with bullish MACD crossover
  • RSI approaching oversold territory
  • Stable volume but bearish SMA alignment

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF fair value implies ~77% upside
  • Revenue growth of 19.5% and strong operating margins
  • Low payout ratio supports dividend sustainability

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Undervalued relative to industry P/E and strong cash flow generation
  • Consistent dividend with low payout ratio
  • Growth profile with expanding security and automation markets

Key Metrics & Analysis

Financial Health

Revenue Growth19.50%
Profit Margin8.76%
P/E Ratio16.5
ROE12.50%
ROA6.50%
Debt/Equity96.25
P/B Ratio1.9
Op. Cash Flow$241.5M
Free Cash Flow$152.6M
Industry P/E28.1

Technical Analysis

TrendBearish
RSI31.4
Support$40.01
Resistance$49.59
MA 20$43.92
MA 50$48.68
MA 200$55.94
MACDBullish
VolumeStable
Fear & Greed Index65.98

Valuation

Fair Value$61.56
Target Price$73.00
Upside/Downside77.40%
GradeUndervalued
TypeGrowth
Dividend Yield1.75%

Risk Assessment

Beta1.21
Volatility29.58%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.